Hepatitis aguda inducida por acarbosa

Fernández, Alberto Benavente; Gacía, Antonio Maraver; Fabuel, A. Talavera; Merino, Antonio Barrios

doi:10.1016/s0025-7753(01)72098-2

Cited by 7 publications

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several clinical trials have reported elevated liver enzyme levels in patients who received AGIs therapy compared with those who received a placebo 2 3 . Several case reports have already reported reversible hepatotoxicity after AGIs use 4 5 6 7 , along with re-exposure confirmation. The exact mechanism of AGIs-induced liver injury is idiosyncratic 8 .…”

mentioning

confidence: 89%

Risk of liver injury after α-glucosidase inhibitor therapy in advanced chronic kidney disease patients

et al. 2016

Sci Rep

View full text Add to dashboard Cite

Although α-glucosidase inhibitors (AGIs) are commonly used for controlling postprandial blood glucose, AGIs-induced liver injuries have been reported. However, the relationship between AGIs and liver injuries in advanced chronic kidney disease (CKD) patients remains unexplored. In this nationwide case-control study, we recruited 1765 advanced diabetic CKD patients, who received AGIs therapy from January 1, 2000 to December 31, 2010 as the study sample and 5295 matched controls. Recent and former AGIs users were defined as patients who received the AGIs prescription for 30–60 d and 30–210 d before the event of liver injury. The risk of AGIs-induced liver injury was examined using time-dependent Cox proportional hazards model. Liver injury occurred in 3.9% of patients in the study group and 3.3% of patients in the control group. AGIs use did not increase the risk of liver injury in advanced CKD patients (P = 0.19). The stratified analysis indicated no increased risk of liver injury in all AGIs-using subgroups (all P > 0.05). The available evidence supports extending the use of AGIs without increasing the risk of liver injury in patients with advanced CKD. Additional randomized controlled trials are warranted to confirm our results.

show abstract

mentioning

confidence: 89%

Risk of liver injury after α-glucosidase inhibitor therapy in advanced chronic kidney disease patients

et al. 2016

Sci Rep

View full text Add to dashboard Cite

show abstract

Current Awareness

2002

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 19 sections: 1 Books, Reviews & Symposia; 2 General; 3 Anti‐infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non‐steroidal Anti‐inflammatory Agents; 7 CNS Agents; 8 Anti‐neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator‐Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti‐inflammatory Agents ‐ Steroidal; 19 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.

show abstract

Alpha-glucosidase inhibitors

Horikawa

Takeda²

2006

Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions

View full text Add to dashboard Cite

Hepatitis aguda inducida por acarbosa

Cited by 7 publications

References 6 publications

Risk of liver injury after α-glucosidase inhibitor therapy in advanced chronic kidney disease patients

Risk of liver injury after α-glucosidase inhibitor therapy in advanced chronic kidney disease patients

Current Awareness

Alpha-glucosidase inhibitors

Contact Info

Product

Resources

About